Citius Oncology Inc. (CTOR)
NASDAQ: CTOR
· Real-Time Price · USD
0.83
-0.04 (-4.40%)
At close: May 01, 2025, 3:20 PM
-4.40% (1D)
| Bid | 0.78 |
| Market Cap | 59.7M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -6.66M |
| EPS (ttm) | -0.33 |
| PE Ratio (ttm) | -2.53 |
| Forward PE | -22 |
| Analyst | Buy |
| Ask | 0.89 |
| Volume | 71,524 |
| Avg. Volume (20D) | 1,315,211 |
| Open | 0.85 |
| Previous Close | 0.87 |
| Day's Range | 0.82 - 0.89 |
| 52-Week Range | 0.55 - 49.00 |
| Beta | -0.19 |
About CTOR
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc....
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date n/a
Employees NaN
Stock Exchange NASDAQ
Ticker Symbol CTOR
Analyst Forecast
According to 2 analyst ratings, the average rating for CTOR stock is "Buy." The 12-month stock price forecast is $4.5, which is an increase of 439.31% from the latest price.
Stock Forecasts